GENETICALLY ENGINEERED ORAL VACCINES AND CARIES IMMUNITY
基因工程口服疫苗和龋齿免疫
基本信息
- 批准号:2872148
- 负责人:
- 金额:$ 23.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1996
- 资助国家:美国
- 起止时间:1996-02-01 至 2001-01-31
- 项目状态:已结题
- 来源:
- 关键词:Peyer's patches Salmonella Salmonella vaccines Streptococcus mutans bacterial antigens biotechnology cholera toxin dental caries vaccine drug administration rate /duration electron microscopy enzyme linked immunosorbent assay genetic promoter element gram negative bacteria immunofluorescence technique immunogenetics immunomodulators laboratory rat lymphocyte molecular cloning mucosal immunity nonhuman therapy evaluation oral administration recombinant DNA transfection /expression vector vaccine development vector vaccine
项目摘要
Dental caries is an infectious disease in which the major etiologic agents
in humans are Streptococcus mutans and Streptococcus sobrinus. Studies
aimed at inducing immunity against infectious diseases, including dental
caries, have provided valuable information on microbial antigens important
in inducing protective responses; on the role of IgA antibodies in defense
against infections which invade or colonize surfaces bathed by external
secretions; and on the mechanisms involved in inducing immune responses.
Concurrent with these studies, the advancements in recombinant DNA
technology and gene cloning have led to additional information on
microbial gene products important in virulence and to the development of
novel vaccines. The overall goal of this project is to define mechanisms
by which mucosal vaccines consisting of recombinant, avirulent Salmonella
strains expressing cloned genes of mutans streptococci, with and without
adjuvant, induce specific immune responses. Specifically, we will: l)
Determine the effectiveness of Salmonella expressed cloned B subunit of
cholera toxin (CTB) in promoting immune responses to co-expressed cloned
antigens of mutans streptococci. The levels and isotype of antibodies to
the cloned antigens in serum and external secretions of mice and rats
immunized orally with Salmonella expressing chimeric proteins will be
measured by ELISA to determine the immunogenic and adjuvant properties of
the different types of fusions between antigen and CTB in vivo. Analysis
of caries activity in a rat model will assess the protective effect of the
responses. These studies will determine which structural type of chimeric
protein, when expressed by Salmonella in vivo, is most effective in
promoting salivary IgA antibody responses protective against mutans
streptococci. 2) Determine the effect of the Salmonella vaccine strain,
vector, and promoter on the expression of cloned antigen of mutans
streptococci and on the induction of immune responses. The amount of
cloned antigen of mutans streptococci produced by Salmonella mutant
strains containing expression vectors with different promoters and
replicons will be measured by ELISA. Stability of the expression vectors
will be assessed by microbiologic detection of Salmonella in tissues of
mice orally-immunized with the Salmonella vaccine. The level and isotype
of antibodies to the cloned antigen in serum and external secretions of
animals orally immunized with a Salmonella strain containing different
vectors will be measured to determine if differences exist in the
magnitude and duration of the mucosal immune responses and in protection
against infection by mutans streptococci. These studies will determine the
effect of the vector replicon on the in vivo expression of cloned protein
and on the induction of immune responses, and whether immune responses
induced by the in vivo expression of cloned protein under the control of
a constitutive promoter (trc) versus one induced in an anaerobic
environment (nirB) are of greater magnitude and longer duration. 3)
Determine the effect of route of immunization with a recombinant
Salmonella vaccine on the magnitude and protective capability of the
salivary IgA antibody response. The level of IgA antibodies to the cloned
antigen in saliva in animals immunized by the oral or intranasal route
will be measured by ELISA to determine which route of immunization induces
the highest salivary IgA antibody response protective against infection by
mutans streptococci. The results of these studies will be relevant in
establishing the practicability of Salmonella vaccine delivery systems for
the induction of protective immune responses against mucosal pathogens
including those associated with the oral cavity.
龋齿是一种感染性疾病,其中的主要病原
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Suzanne M. Michalek其他文献
Cellular events leading to immunity following ingestion of food antigen
- DOI:
10.1016/s0091-6749(73)80082-x - 发表时间:
1973-02-01 - 期刊:
- 影响因子:
- 作者:
Richard M. Rothberg;Sumner C. Kraft;Suzanne M. Michalek - 通讯作者:
Suzanne M. Michalek
Polymer vesicles for the delivery of inhibitors of cariogenic biofilm
- DOI:
10.1016/j.dental.2024.09.006 - 发表时间:
2024-11-01 - 期刊:
- 影响因子:
- 作者:
Parmanand Ahirwar;Veronika Kozlovskaya;Piyasuda Pukkanasut;Pavel Nikishau;Sarah Nealy;Gregory Harber;Suzanne M. Michalek;Linto Antony;Hui Wu;Eugenia Kharlampieva;Sadanandan E. Velu - 通讯作者:
Sadanandan E. Velu
Suzanne M. Michalek的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Suzanne M. Michalek', 18)}}的其他基金
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
- 批准号:
6864867 - 财政年份:2003
- 资助金额:
$ 23.3万 - 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
- 批准号:
6798161 - 财政年份:2003
- 资助金额:
$ 23.3万 - 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
- 批准号:
7029667 - 财政年份:2003
- 资助金额:
$ 23.3万 - 项目类别:
Development of a Mucosal Vaccine Against Francisella tularensis
土拉弗朗西斯菌粘膜疫苗的研制
- 批准号:
7209733 - 财政年份:2003
- 资助金额:
$ 23.3万 - 项目类别:
Development of a Mucosal Vaccine Against F. tularensis
土拉弗朗西斯粘膜疫苗的研制
- 批准号:
6689492 - 财政年份:2003
- 资助金额:
$ 23.3万 - 项目类别:
BACTEROIDES LPS/CYTOKINE REGULATION IN INFLAMED GINGIVAL TISSUE
发炎牙龈组织中拟杆菌脂多糖/细胞因子的调节
- 批准号:
6104731 - 财政年份:1998
- 资助金额:
$ 23.3万 - 项目类别:
BACTEROIDES LPS/CYTOKINE REGULATION IN INFLAMED GINGIVAL TISSUE
发炎牙龈组织中拟杆菌脂多糖/细胞因子的调节
- 批准号:
6270281 - 财政年份:1997
- 资助金额:
$ 23.3万 - 项目类别:
GENETICALLY ENGINEERED ORAL VACCINES AND CARIES IMMUNITY
基因工程口服疫苗和龋齿免疫
- 批准号:
2130299 - 财政年份:1996
- 资助金额:
$ 23.3万 - 项目类别:
Genetically Engineered Oral Vaccines & Caries Immunity
基因工程口服疫苗
- 批准号:
6708881 - 财政年份:1996
- 资助金额:
$ 23.3万 - 项目类别:
Genetically Engineered Oral Vaccines & Caries Immunity
基因工程口服疫苗
- 批准号:
6634618 - 财政年份:1996
- 资助金额:
$ 23.3万 - 项目类别:
相似海外基金
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
- 批准号:
10432065 - 财政年份:2019
- 资助金额:
$ 23.3万 - 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
- 批准号:
9978709 - 财政年份:2019
- 资助金额:
$ 23.3万 - 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
- 批准号:
10201474 - 财政年份:2019
- 资助金额:
$ 23.3万 - 项目类别:
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccines
用于广谱抗沙门氏菌疫苗的合成聚糖与噬菌体 Qbeta 缀合物
- 批准号:
10653943 - 财政年份:2019
- 资助金额:
$ 23.3万 - 项目类别:
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines
病毒样颗粒作为碳水化合物抗沙门氏菌疫苗的载体
- 批准号:
9118056 - 财政年份:2015
- 资助金额:
$ 23.3万 - 项目类别:
Virus like particles as carriers for carbohydrate based anti-Salmonella vaccines
病毒样颗粒作为碳水化合物抗沙门氏菌疫苗的载体
- 批准号:
8823965 - 财政年份:2015
- 资助金额:
$ 23.3万 - 项目类别:
Rabbit model to assess reactogenicity and immunogenicity of Salmonella vaccines
用于评估沙门氏菌疫苗反应原性和免疫原性的兔模型
- 批准号:
8607893 - 财政年份:2013
- 资助金额:
$ 23.3万 - 项目类别:
Rabbit model to assess reactogenicity and immunogenicity of Salmonella vaccines
用于评估沙门氏菌疫苗反应原性和免疫原性的兔模型
- 批准号:
8490135 - 财政年份:2013
- 资助金额:
$ 23.3万 - 项目类别:
Evaluation of Protein Channel-Attenuated Salmonella Vaccines
蛋白质通道减毒沙门氏菌疫苗的评价
- 批准号:
7849975 - 财政年份:2009
- 资助金额:
$ 23.3万 - 项目类别:
Evaluation of Protein Channel-Attenuated Salmonella Vaccines
蛋白质通道减毒沙门氏菌疫苗的评价
- 批准号:
7661304 - 财政年份:2009
- 资助金额:
$ 23.3万 - 项目类别:














{{item.name}}会员




